Note: Descriptions are shown in the official language in which they were submitted.
CA 02387199 2002-04-11
i
DESCRIPTION
Remedies for intractable wound
TECHNICAL FIELD
This invention relates to a therapeutic drug for
refractory injuries, comprising a substance having a human
leucocyte elastase inhibitory activity as an effective
ingredient.
The inventors of this invention have found that a
substance having a human leucocyte elastase inhibitory
activity is effective for the treatment of refractory
injuries and have completed this invention.
BACKGROUND ART
INDUSTRIAL APPLICABILITY
This invention is a therapeutic drug for refractory
injuries, comprising a substance having a human leucocyte
elastase inhibitory activity as an effective ingredient.
DISCLOSURE OF THE TNVENTION
The substance having a human leucocyte elastase
inhibitory activity and being usable as an effective
ingredient of a therapeutic drug for refractory injuries may
be any substance having a human leucocyte elastase inhibitory
activity. Furthermore, the substance having a human
leucocyte elastase inhibitory activity and being usable in
this invention includes not only substances that directly
inhibit leucocyte elastase but also substances that
indirectly inhibit leucocyte elastase by suppressing the
infiltration of leucocytes or by inhibiting the generation of
elastase. In other words, various substances having such an
activity are known. Not only the known substances but also
new substances can also be used if they have the human
leucocyte elastase inhibitory. Among these, particularly
1
CA 02387199 2002-04-11
suitable compounds are exemplified below.
(1) WS7622A mono- or disulfate ester and pharmaceutically
acceptable salts thereof: among them, the disodium salt of
the WS7622A disulfate ester and the dipotassium salt of the
WS7622A disulfate ester are known substances having the
following physico-chemical properties respectively (Japanese
Laid-open Patent Application No. Hei 4-279600).
Disodium salt of WS7622A Bisulfate ester
Appearance: colorless crystal
Solubility: soluble: water, methanol
insoluble: chloroform, n-hexane
Melting point: 257 to 263°C (dec.)
Specific rotation: [a]23p +37.5° (C=1, methanol)
Molecular formula: C17H61N9019S2Na2
Elemental analysis:
Calcd for C1~H61N9019SZNa2 ~ 6H20
C 44.30, H 5.77, N 9.89, S 5.03, Na 3.61 ~
Found: C 49.98, H 5.90, N 10.06, S 5.00, Na 3.98
Molecular weight: FAB-MS m/z 1188 (M+Na)+
Thin layer chromatography:
Stationary phase Developing solvent Rf value
Silica gel CHC13-CH30H-Hz0 0.11
(Merck Art 5715) (65 . 25 . 4)
n-butanol-acetic acid-water 0.29
Infrared absorption spectrum:
YKBrmax: 3360, 2960, 1735, 1660, 1640, 1530, 1500, 1380,
1250, 1200, 1060, 1030, 940, 890 cm 1
1H Nuclear magnetic resonance spectrum:
(400 MHz, Dz0) b
7 . 50 ( 1H, s )
7.27 (1H, s)
7.33-7.24 (3H, m)
2
f
CA 02387199 2002-04-11
6 . 99 ( IH, q, J=7Hz )
6.85 (2H, br d, J=8Hz)
5.53 (1H, m)
5.37 (1H, m)
9.80 (1H, br s)
4.63-4.57 (2H, m) '
4.53 (1H, m)
4.06 (1H, m)
3.99 (1H, d, J=IOHz)
3.56 (1H, br d, J=l4Hz)
3.46 (1H, m)
2.97 (3H, s)
2.97-2.88 (2H, m)
2.72 (1H, m)
2.59 (1H, m)
2.51-2.38 (2H, m)
2.09-1.91 (9H, m)
1.82-1.60 (3H, m)
1.77 (3H, d, J=7Hz)
1.50 (3H, d, J=6.5Hz)
1.40 (1H, m)
1 . 11 ( 6H, d, J=7Hz )
0.99 (3H, d, J=6.5Hz)
0.97 (3H, d, J=6.5Hz)
13C Nuclear magn etic ance spectrum:
reson
( 100 MHz, D20)
b
183.6 (s)
177.9 (s)
177.7 (s)
174.8 (s)
173.8 (s)
173.3 (s)
172.4 (s)
167.8 (s)
161.5 (s)
3
CA 02387199 2002-04-11
145.5
144.9 (S)
139.6 (d)
139.0 (S)
137.0
136.0 (S) ;
132.3 (d) x 2
131.0 (d) x 2
129. 6 (d)
127.9 (d)
125.9 (d)
77.4 (d)
75.1 (d)
63.8 (d)
62.7 (d)
59.1 (d)
55.9 (d)
54.9 (d)
51.9 (d)
41.9 (t)
37.2 (d)
36.9 (t)
34.1 (q)
32.3 (d)
31.9 (t)
31.8 (t)
31.2 (t)
27.5 (t)
23.7 (t)
21.7 (q)
21.4 (q) x 2
21.3 (q)
21.1 (q)
15.5 (q)
9
' CA 02387199 2002-04-11
Amino acid analysis
The disodium salt (1 mg) of the WS7622A disulfate ester
was hydrolyzed in 6N hydrochloric acid (1 ml) at 110°C for 20
hours, and dried under reduced pressure to obtain a mixture.
The mixture was measured by Hitachi 835 Automatic Amino Acid
. Analyzer. Type H (Wako code: 013-08391) and type B (Wako
code: 016-08641) of Wako Pure Chemical Industries, Ltd, were
used as standard amino acid samples.
As a result, threonin, valine, phenyl alanine,
ornithine, ammonia and several kinds of unknown ninhydrin
positive components were detected.
The following formula is proposed as a partial chemical
structural formula of the disodium salt of the WS7622A
Bisulfate ester.
CH3 OS03Na
O 0 CH N
H
CH3 N OS03Na
H3 .H ~ . ,H ~ ~ \
i n
H
~ N
2 5 C H / 'O N
3
CH3 ~CH3
Dipotassium salt of the WS7622A Bisulfate ester
Appearance: colorless amorphous powder
Solubility: soluble: water; methanol
insoluble: chloroform, n-hexane
Melting point: 230 to 237°C (dec.)
Specific rotation: [a]23p +39° (C=l, methanol)
5
CA 02387199 2002-04-11
Molecular formula : C1~H61N9019SZK2
Elemental analysis:
Calcd for C1~H61N9019S2Kz~ 6H20
C 93.21, H 5.63, N 9.65, S 4.91, K 5.99 %
Found: C 43.96, H 5.44, N 9.97, S 5.09, K 4.49
Molecular weight: FAB-MS m/z 1236 (M+K)+
Thin layer chromatography:
_Stationary phase Developing solvent Rf value
Silica gel CHC13-CH30H-H20 0.13
(Merck Art 5715) (65 . 25 . 4)
Infrared absorption spectrum:
YKBrmax: 3360, 2960, 1735, 1660, 1690, 1530, 1500, 1405,
1380, 1250, 1200, 1050, 1030, 910, 890 cm 1
1H Nuclear magnetic resonance
spectrum:
(400 MHz, D20) b
7.52 (1H, s)
7.28 (1H, s)
7.34-7.25 (3H, m)
6.96 (1H, q, J=7Hz)
6.87 (2H, br d, J=8Hz)
5.56 (1H, m)
5.40 (1H, m)
4.84 (1H, br s)
4.70-4.55 (3H, m)
4.10 (1H. m)
4 . 03 ( 1H, m)
3.60 (1H, br d, J=l4Hz)
3.50 (1H, m)
3.00 (3H, s)
3.00-2.85 (2H, m)
2.76 (1H, m)
2 . 62 ( 1H, m)
2.55-2.90 (2H, m)
2 . 12-1 . 95 ( 4H, m)
6
CA 02387199 2002-04-11
1.90-1.65 (3H, m)
1.79 (3H, d, J=7Hz)
1.53 (3H, d, J=6.5Hz)
1.95 (1H, m)
1.19 (6H, d, J=7Hz)
1 . 02 ( 3H, d, J=6. 5Hz
)
1.00 (3H, d, J=5.5Hz)
Amino acid analysis
The dipotassium salt (1 mg) of the WS7622A Bisulfate
ester was hydrolyzed in 6N hydrochloric acid (1 ml) at 110°C
for 20 hours, and dried under reduced pressure to obtain a
mixture. The mixture was measured by Hitachi 835 Automatic
Amino Acid Analyzer. Type H (Wako code: 013-08391) and type
B (Wako code: 016-08641) of Wako Pure Chemical Industries,
Ltd. were used as standard amino acid samples.
As a result, threonin, valine, phenyl alanine,
ornithine, ammonia and several kinds of unknown ninhydrin
positive components were detected.
The following formula is proposed as a partial chemical
structural formula of the dipotassium salt of the WS7622A
Bisulfate ester.
CH3 OS03K
O 0 CH
H
CH3 N OS03K
'H ~ ~ \
H3
0 I o
H
~ N
CH3~0 N
d
CH3 ~CH3
7
CA 02387199 2002-04-11
Pharmaceutically acceptable salts of the WS7622A mono-
or disulfate ester may include a mono- or disalt with an
inorganic or organic base, for example, an alkali metal salt
(e. g., sodium salt, potassium salt, etc.), an alkaline earth
metal salt (e.g., calcium salt, etc.), an ammonium salt, an
ethanolamine salt, a triethylamine salt, a dicyclohexylamine
salt, a pyridine salt, etc.
The WS7622A substance, a starting substance for the
synthesis of the above-mentioned WS7622A mono- or disulfate
ester, also has the human leucocyte elastase inhibitory
activity and can be used as a therapeutic drug for refractory
injuries. The substance is known as a substance having the
following physico-chemical properties (Japanese Laid-open
Patent Application No. Hei 3-218387 and Japanese Laid-open
Patent Application No. Hei 4-279600).
Physico-chemical properties of the WS7622A substance
Appearance: colorless prism crystal
Property of substance: acidic
Color reaction:
Positive: cerium sulfate reaction, iodine vapor
reaction, ferric chloride reaction
Negative: ninhydrin reaction, Molisch reaction,
Dragendorff reaction
Solubility: soluble: methanol, ethanol, n-butanol
slightly soluble: chloroform, acetone, ethyl
acetate
insoluble: water, n-hexane
Thin layer chromatography (TLC):
Chloroform-methanol (5 . 1, v/v)
Rf value 0.51
Acetone-methanol (10 . 1)
Rf value 0.62
(Kiesel gel 60F25i silica gel plate, Merck)
8
CA 02387199 2002-04-11
Melting point: 250 to 252°C (dec.)
Specific rotation: [a]?3p +36° (C=1, methanol)
UV spectrum: ~MeOHmax 287 nm (~ = 3600)
~MeOH-HClmax 2 8 7 nm
~MeOH-NaOHmax 2 9 8 nm
Molecular formula: C17H63NgO13
Elemental analysis:
Calcd for C1~H63N9O13' 2Hz0
C 56.56, H 6.77, N 12.63 %
Found: C 56.65, H 6.62, N 12.27
Molecular weight: FAB-MS m/z 984 (M+Na)+
Infrared absorption
spectrum:
: 3400 3300, 3060, 2980, 2940, 1735, 1710, 1690,
YKBr
,
max
1670, 1660, 1640, 1540, 1520, 1470, 1380, 1330,
1300, 1260, 1220, 1200, 1160, 1130, 1090, 1000,
980, 940, 920 cm 1
1H Nuclear magnetic
resonance spectrum:
(400 MHz, CD 30D) b
7.22-7.09 (3H, m)
6.88-6.77 (3H, m)
6.74 (1H, s)
6.46 (1H, s)
5 . 4 6 ( 1H, m)
2S 5.18 (1H, s)
4.85 (1H, s)
9.77 (1H, m)
4 . 65 ( 1H, m)
4.50 (1H, m)
3.96 (1H, m)
3.91 (1H, d, J=9Hz)
3.60-3.47 (2H, m)
3.03 (1H, m)
2.90 (3H, s)
2.86 (1H, m)
9
CA 02387199 2002-04-11
2.59-2.99 (2H, m)
2.39 (1H, m)
2.29-2.16 (2H, m)
2.00 (1H, m)
1.89 (1H, m)
1.74 (3H, d, J=6Hz)
1. 72-1 . 53 ( 4H, m)
1.44 (3H, d, J=6Hz)
1.12 (1H, m)
1.10 (6H, d, J=6Hz)
0.99 (3H, d, J=6Hz)
0 . 94 ( 3H, d, J=6Hz )
isC Nuclear magn etic ance spectrum:
reson
(100 MHz, CD30D)S
179.7 (s)
176.3 (s)
174.7 (s)
173.3 (s)
172.4 (s)
171.4 (s)
170.3 (s)
165.8 (s)
160.2 (s)
145.7 (s)
145.6 (s)
137.5 (s)
134.0 (d)
131.4 (s)
130.6 (d) x
2
129.8 (s)
129.1 (d) x
2
129.1 (s)
127.6 (d)
119.1 (d)
118.0 (d)
CA 02387199 2002-04-11
76. 0 (d)
73.4 (d)
63,1 (d)
61.9 (d)
57,1 (d)
53.6 (d)
52.7 (d)
50.5 (d)
39.9 (t)
36.1 (t)
35.8 (d)
31.8 (q)
31.0 (t)
30.8 (d)
29. 9 (t)
29.7 (t)
25.2 (t)
22.3 (t)
20.2 (q)
20.0 (q) x 2
I9.7 (q)
19.5 (q)
13.3 (q)
Amino acid analysis
WS7622A(1 mg) was hydrolyzed in 6N hydrochloric acid (1
ml) at 110°C for 20 hours, and dried under reduced pressure
to obtain a mixture. The mixture was measured by Hitachi 835
Automatic Amino Acid Analyzer. Type H (Wako code: 013-08391)
and type B (Wako code: 016-08641) of Wako Pure Chemical
Industries, Ltd. were used as standard amino acid samples.
As a result, threonin, valine, phenyl alanine,
ornithine, ammonia and several kinds of unknown ninhydrin
positive components were detected.
11
CA 02387199 2002-04-11
The following formula is proposed as a partial chemical
structural formula of the WS7622A.
CH3 OH
O O CH
H
CH3 N OH
'H ~ 'H
H3
n ~ n
H
~ N
CH3 '0 N
CH3 ~CHg
Salts of the WS7622A substance may include a salt with
an inorganic or organic base, for example, an alkali metal
salt (e. g,, sodium salt, potassium salt, etc.), an alkaline
earth metal salt (e. g., calcium salt, etc.), an ammonium salt,
an ethanolamine salt, a triethylamine salt, a
dicyclohexylamine salt, etc.
Similarly, WS7622B, WS7622C and WS7622D substances and
their derivatives (Japanese Laid-open Patent Application No.
Hei 3-218387), having the human leucocyte elastase inhibitory
activity, can also be used as therapeutic drugs for
refractory injuries.
The above-mentioned WS7622A substance (similarly,
WS7622B, WS7622C and WS7622D substances) can be produced by
culturing the streptomyces resistomycificus No. 7622 strain,
for example. The fungal strain was deposited with National
Institute of Bioscience and Human-Technology, an
international depository authority on the Budapest Treaty,
3S under the deposit number FERM BP-2306.
12
CA 02387199 2002-04-11
(2) Trifluoromethylketone derivative represented by the
following formula:
R2 R3
R1 NHCO ~ ~ X-CONHCHCO-Y-CONHCHCOCFg
in which R1 is lower alkyl having one or two substituents
selected from a group consisting of carboxy, esterified
carboxy and di-lower alkylcarbamoyl; phenyl(lower)alkyl which
may have halogen, amino or nitro at the phenyl moiety and may
have carboxy or esterified carboxy at the alkyl moiety;
halophenyl; morpholino; or morpholino(lower)alkyl,
R2 and R3 are each lower alkyl,
X is - or -NH-,
r
Y is -N or ~ .
NCH2
and a pharmaceutically acceptable salt thereof.
(3) Trifluoromethylketone derivative represented by the
following formula:
R2
R1 NHCO ~ ~ CONH~HCON
R
ONHCHCOCF3
in which R1 to R3 are the same as those of the above-
mentioned compound (2),
and a pharmaceutically acceptable salt thereof.
(4) 3(RS)-[[4-(carboxymethylaminocarbonyl)phenylcarbonyl]-L-
valyl-L-prolyl]amino-1,1,1-trifluoro-9-methyl-2-oxopentane or
13
CA 02387199 2002-04-11
a sodium salt thereof
The compounds described at the above items (2) to (4)
are known compounds described in Japanese Laid-open Patent
Application No. Hei 4-297446. In addition, pharmaceutically
acceptable salts of the compounds described at the items (2)
to (4) may include a salt with an inorganic or organic base,
far example, an alkali metal salt (e. g., sodium salt,
potassium salt, etc.), an alkaline earth metal salt (e. g.,
calcium salt, etc.), an ammonium salt, an ethanolamine salt,
a triethylamine salt, a dicyclohexylamine salt, etc., and an
organic or inorganic acid addition salt, for example,
methanesulfonate, hydrochloride, sulfate, nitrate, phosphate,
etc.
Suitable examples of the above-mentioned definitions
are explained in detail as follows.
The term "lower" is intended to means 1 to 6 carbon
atoms, unless otherwise indicated.
Suitable examples of "halogen" may include fluorine,
chlorine, bromine and iodine.
Suitable "lower alkyl" may include a straight or
branched alkane residue having 1 to 6 carbon atoms, such as
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,
pentyl, neo-pentyl, hexyl and the like, preferably those
having 1 to 4 carbon atoms.
Suitable "esterified carboxy" may be alkyl ester, that
is, alkoxycarbonyl, for example, lower alkoxycarbonyl (e. g.
methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
butoxycarbonyl, tert-butoxycarbonyl, etc.) and
phenyl(lower)alkyl ester, that is, phenyl(lower)alkoxy
carbonyl, for example, benziloxycarbonyl, and
benzoyl(lower)alkyl ester, that is, benzoyl(lower)alkoxy
carbonyl, for example, benzoylmethoxycarbonyl, etc.
Suitable "lower alkylene" may include methylene,
19
CA 02387199 2002-04-11
ethylene, propylene, isopropylene, etc.
Suitable "di-lower alkylcarbamoyl" may include N,N-
dimethylcarbamoyl, N,N-diethylcarbamoyl, etc.
(5) FR901951 substance having the following physico-chemical
properties and a pharmaceutically acceptable salt thereof
Appearance: white powder
Color reaction:
Positive: cerium sulfate, iodine vapor, Ehrlich,
ninhydrin
Negative: Molisch
Solubility: soluble: water, methanol, dimethyl sulfoxide
hardly soluble: acetone
insoluble: ethyl acetate
Melting point: 243 to 245°C (dec.)
Specific rotation: [a]23p -15° (C=0.65, H20)
UV absorption spectrum: ~MeOHmax nm (~) 275 = (4300)
281 (9500), 290 (3900)
Molecular formula : C6pH~gN13O18
Elemental analysis:
Calcd for C5pH79N1301B' 10H20
C 49.68, H 6.88, N 12.55
Found: C 49.95, H 6.28, N 12.42 °s
Molecular weight: FAB-MS m/z 1270 (M+H)+
Thin layer chromatography:
Stationary phase Developing solvent Rf value
Silica gel CHC13 : MeOH: NH90H 0.60
(Merck) (15 . 11 . 5)
RP-18 70°s hydrous methanol 0.32
(Merck)
FT Infrared absorption spectrum:
YK$rmax: 3390, 3070, 2970, 2880, 1740, 1660, 1530, 1450,
1410, 1380, 1350, 1250, 1190, 1110, 1080, 1010,
750, 700, 670, 660, 620, 600 cm-~
CA 02387199 2002-04-11
1H Nuclear magnetic
resonance spectrum:
(400 MHz, DZO) b
7.70 (1H, d, J=7Hz)
7.52 (1H, d, J=7.5Hz)
7.99-7.23 (7H, m)
7.22 (1H, s)
5.59 (1H, q, J=7Hz)
9.99 (1H, t, J=4.5Hz)
9.85-9.74 (3H, m)
4.58 (1H, dd, J=6Hz, lOHz)
9.45-4.35 (3H, m)
4.30 (1H, dd, J=4Hz, 7Hz)
9.07 (1H, m)
3.99 (1H, dd, J=lOHz, 4.5Hz)
3.66-3.50 (3H, m)
3.49-3.25 (4H, m)
3.16-2.93 (9H, m)
2.87 (1H, d, J=l8Hz)
2.80-2.68 (2H, m)
2.56-2.48 (2H, m)
2.08 (1H, dd, J=l6Hz, 9Hz)
1.87-1.53 (9H, m)
1.43 (3H, d, J=7Hz)
1.30 (3H, d, J=6.5Hz)
1.95-1.17 (4H, m)
0.95 (3H, d, J=6Hz)
0.89 (3H, d, J=6Hz)
i3C Nuclear magn etic resonance
spectrum:
( 100 MHz, D20) b
177.2 (s) 130.0 (d) x 2 56.0 (d) 31.9 (t)
176.5 (s) 129.8 (d) x 2 54.1 (d) 28.8 (t)
174.6 (s) 128.5 (d) 53.8 (d) 26.6 (t)
179.2 (s) 127.8 (d) 53.2 (d) 25.1 (d)
174.0 (s) 125.5 (d) 53.1 (d) 23.2 (q)
173.2 (s) 123.2 (d) 52.9 (d) 23.2 (t)
16
CA 02387199 2002-04-11
173.0 (s) 120.9 (d) 52.8 (d) 23.1 (t)
172.8 (s) 118.7 (d) 99.5 (d) 20.8 (q)
172.6 (s) 113.1 (d) 48.6 (t) 19.4 (q)
172.5 (s) 108.8 (s) 40.1 (t) 18.3 (q)
172.1 (s) 73.3 (d) 39.6 (t)
171.7 (s) 69.7 (d) 39.4 (t)
171.9 (s) 64.3 (d) 38.9 (t)
170.3 (s) 62.1 (d) 35.3 (t)
137.2 (s) 60.9 (d) 39.8 (t)
IO 136.0 (s) 57.1 (d) 31.7 (t)
The above-mentioned FR90145 substance is known as a
substance produced from the FR90195 substance producing
fungus of the flexibacter genus (for example, International
Publication No. W093/02203). In addition, the flexibacter sp
No. 758 strain of the producing fungus was deposited with
National Institute of Bioscience and Human-Technology, an
international depository authority on the Budapest Treaty,
under the deposit number FERM BP-3420.
Furthermore, pharmaceutically acceptable salts of the
above-mentioned FR90195 substance may be the same as the
pharmaceutically acceptable salts of the compounds described
at the above-mentioned items (2) to (4).
In addition to those described above, examples of
substances having the elastase inhibitory activity may
include al-antitrypsin, SLP1 (Secretory Leukocyte Protease
Inhibitor) (American Review of Respiratory Disease Vol. 147,
1993, P442-446), urinastatin, colchicine, erythromycin,
clarithromycin, IC1200, 800, ONO-5046 (American Journal of
Respiratory and Critical Care Medicine Vol. 153, P391-397),
antielastase antibody, etc.
Examples of refractory injuries in accordance with this
invention may include ulcers at skin (e. g. decubitus
(bedsore), foot ulcers associated with diabetes, etc.),
17
CA 02387199 2002-04-11
ulcers at feet, stomach, cornea, etc. and the like. The
therapeutic drug for refractory injuries in accordance with
this invention is particularly suited for the treatment of
refractory skin ulcers, such as foot ulcers associated with
diabetes, among the above-mentioned ulcers.
The therapeutic drug for refractory injuries in
accordance with this invention is usually used as external
preparations (e. g. lotions, ointments, plasters, liniments,
aerosols, suspensions, emulsions, etc.) in the case of
refractory skin ulcers, for example. In addition, the
therapeutic drug can be used in the forms of conventional
pharmaceutical preparations, such as powders, fine granules,
granules, tablets, dragees, injection solutions,
insufflations, microcapsules, capsules, suppositories,
solutions, syrups, etc.
If necessary, there may be included in the above
preparations diluents, disintegrating agents (e. g. sucrose,
starch, crystalline cellulose, L-hydroxypropylcellulose,
synthetic aluminum silicate, etc.), binders (e. g. cellulose,
methylcellulose, hydroxypropylcellulose,
hydroxypropylmethylcellulose, polypropylpyrrolidone,
polyvinylpyrrolidone, gelatin, gum Arabic, polyethylene
glycol, etc.), coloring agents, sweeteners, lubricants (e. g.
magnesium stearate, etc.) and the like.
While the dosage of the therapeutic drug for refractory
injuries in accordance with this invention varies depending
on the condition and the like of each patient to be treated,
in the case of external administration, a dose of about
0.001-10% of the substance having a human leucocyte elastase
inhibitory activity or a pharmaceutically acceptable salt
thereof should be used generally.
Next, the effects of this invention are described by
using a test example.
18
CA 02387199 2002-04-11
Test example (diabetic rat foot ulcer curing action)
Purpose:
The action of the compound (applied) in accordance with
this invention on a foot ulcer induced by acetic acid was
examined by using normal and diabetic rats.
Compound used for the test:
Sodium salt of 3(RS)-[[4-(carboxymethylaminocarbonyl)
phenylcarbonyl]-L-valyl-L-prolyl]amino-1,1,1-trifluoro-4-
methyl-2-oxopentane (FR136706)
Method:
Diabetes was induced in each of a seven-week-old male
SD rats by intravenously administrating 60 mg/kg
streptozotocin (STZ) to its tail. Fourteen days after the
administration of STZ, 20 p1 glacial acetic acid was
administered into the skin of the left foot instep of each of
the diabetic rats and control rats of the same age while
anesthetized using ether, thereby causing necrosis at the
portion. In the case when the necrotic cuticle of the skin
remained two days after the necrosis, the cuticle was removed
surgically. Then, the administration of FR136706 (0.2~
solution in PEG (polyethylene glycol) 400) was started (50 u1
to the affected portion). PEG400 was administered to the
control group in a similar way.
In a period between two days and 25 days after the
administration of acetic acid, swelling scores (0: no
swelling, 1: slight swelling, 2: intermediate swelling, 3:
significant swelling) was checked visually, and the major
axis length and the minor axis length of each ulcer was
measured with vernier calipers. The area of each ulcer was
calculated from the major axis length and the minor axis
length thereof.
19
CA 02387199 2002-04-11
Result:
The swelling scores of the normal rats were highest on
the measurement start day. Then, the rats were recovered and
their scores became zero 22 days after the administration of
the acetic acid. On the other hand, in the case of the
diabetic rats, the peaks of the swelling scores were found
seven days after the administration of the acetic acid.
Although the rats were recovered gradually after that, the
progress of the recovery was slower than that of the normal
rats. FR136706 did not act on the normal rats, but promoted
the recovery of the diabetic rats.
The swelling areas of the diabetic rats were larger
than those of the normal rats, and the contraction of the
areas of the diabetic rats was slower than that of the normal
rats. FR136706 did not act on the normal rats, but it was
recognized that FR136706 tended to promote the contraction of
the ulcer areas of the diabetic rats.
CA 02387199 2002-04-11
Action on foot ulcer models
-Score
-..
Dos- Swelling
score
after
administration
of
Ani- Spec- age acetic
acid
mal imen (%) After After After After After After. After
2 8 11 15 18 22 25
days days days days days days days
PEG 2.5 2.3 1.8 1.0 0.3 0.0 0.0
Nor- 400 0.2 0.2 0.2 0.0 0.2 0.0 0.0
mal (6) (6) (&) (6) (6) (6) (6)
rat FRI 2.5 2.0 1.5 1.0 0.5 0.0 0.0
136706 0.2 0.2 0.2 0.2 0.0 0.2 0.0 0.0
(6) (6) (6) (6) (6) (6) (6)
* ** ** ** **
Dia- PEG 2.2 2.8 2.7 2.2 2.0 1.7 1.5
betic 400 t0.2 0.2 0.2 0.3 0.3 0.3 0.2
rat (6) (6) (6) (6) (6) (6) (6)
FRI 0.2 2.2 2.8 2.5 1.5 1.5 1.2 0.7
136706 0.2 0.2 0.2 0.2 0.2 0.2 0.2
(6) (6) (6) (6) (6) (6) (6)
Average ~ standard error (n)
&, &&: significant at 5°s and 1~ respectively (Wilcoxon Rank
Sum Test)
[Score]
[Scores of PEG400 group of diabetic rats and FRI136706 0.2~
group of diabetic rats on each measurement day]
*, **: significant at 5~ and 1o respectively (Wilcoxon Rank
Sum Test)
[Score]
[Scores of PEG400 group of normal rats and PEG400 group of
diabetic rats on each measurement day]
21
CA 02387199 2002-04-11
Action on foot ulcer models
Ulcer
area
(mm~)
after
administration
of
Ani- Spec- Dos- acetic
acid
mal imen age After After After After After After After
( 2 8 11 15 18 22 25
o
)
days days days days days days days
PEG 58.88 70.29 52.61 24.99 1.51 0.00 0.00
Nor- 400 4.31 6.13 6.36 2.82 0.78 0.00 0.00
mal (6) (6) (6) (6) (6) (6) (6)
rat FRI 58.37 71.42 53.21 28.32 0.69 0.00 0.00
136706 0.2 6.08 8.43 5.11 4.55 0.36 0.00 0.00
(6) (6) (6) (6) (6) (6) (6)
* ** ** **
Dia- PEG 69.28 95.58 86.03 51.63 23.38 15.94 11.05
betic 900 5.33 8.62 7.71 6.12 1.42 3.90 1.68
rat (6) (6) (6) (6) (6) (6) (6)
FRI 69.17 91.77 72.38 41.00 16.10 12.08 6.99
136706 0.2 5.64 6.16 10.37 10.80 6.43 3.73 1.71
(6) (6) (6) (6) (6) (6) (6)
Average ~ standard error (n)
*, **: significant at 5~ and 1~ respectively (Student-t or
Aspin-Welch)
[Ulcer area]
[PEG400 group of normal rats and PEG900 group of diabetic
rats on each measurement day]
22
